RxDoctor Payments Data

Christian Montegut, MD

Family Medicine · Laplace, LANPI 1093970642

Payments from drug & device makers

$6,733in general payments, 2019–2025

Across 418 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$975
  • GSK$692
  • Pfizer$428
  • Novo Nordisk$347
  • Boehringer Ingelheim$262
  • plus $2K from 42 others

What the payments were for

  • Food & beverage$6,63899%
  • Education$951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,733 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$10,827
Medicare patients
47
Services billed
180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide42$63,062
OzempicSemaglutide43$55,511
Trelegy ElliptaFluticasone/Umeclidin/Vilanter79$55,474
JardianceEmpagliflozin49$43,717
JanuviaSitagliptin Phosphate39$27,308
TrulicityDulaglutide17$17,109
VraylarCariprazine Hcl12$16,679
FarxigaDapagliflozin Propanediol20$16,676
MyrbetriqMirabegron19$16,035
EliquisApixaban27$13,044
LinzessLinaclotide16$8,589
SymbicortBudesonide/Formoterol Fumarate23$5,936
Albuterol Sulfate HfaAlbuterol Sulfate120$4,491
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen96$2,518
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen67$1,983

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$975$80,17159 claims
Novo NordiskOzempic$347$55,51143 claims
GSKTrelegy Ellipta$692$55,47479 claims
Boehringer IngelheimJardiance$262$43,71749 claims
MerckJanuvia$76$27,30839 claims
AbbVieVraylar, Linzess, Armour Thyroid$1,591$26,27041 claims
AstraZenecaFarxiga, Symbicort$117$22,61243 claims
Astellas Pharma US IncMyrbetriq$98$16,03519 claims
PfizerEliquis$428$13,04427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Laplace

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →